These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32668277)

  • 1. Pancreatic neuroendocrine tumors with somatostatin expression and paraganglioma-like features.
    Konukiewitz B; von Hornstein M; Jesinghaus M; Steiger K; Weichert W; Detlefsen S; Kasajima A; Klöppel G
    Hum Pathol; 2020 Aug; 102():79-87. PubMed ID: 32668277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic and prognostic significance of multiple hormone expression in pancreatic neuroendocrine tumors.
    Kim JY; Kim MS; Kim KS; Song KB; Lee SH; Hwang DW; Kim KP; Kim HJ; Yu E; Kim SC; Jang HJ; Hong SM
    Am J Surg Pathol; 2015 May; 39(5):592-601. PubMed ID: 25602797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphologic Variants of Pancreatic Neuroendocrine Tumors: Clinicopathologic Analysis and Prognostic Stratification.
    Xue Y; Reid MD; Pehlivanoglu B; Obeng RC; Jiang H; Memis B; Lui SK; Sarmiento J; Kooby D; Maithel SK; El-Rayes B; Basturk O; Adsay V
    Endocr Pathol; 2020 Sep; 31(3):239-253. PubMed ID: 32488621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity.
    Garbrecht N; Anlauf M; Schmitt A; Henopp T; Sipos B; Raffel A; Eisenberger CF; Knoefel WT; Pavel M; Fottner C; Musholt TJ; Rinke A; Arnold R; Berndt U; Plöckinger U; Wiedenmann B; Moch H; Heitz PU; Komminoth P; Perren A; Klöppel G
    Endocr Relat Cancer; 2008 Mar; 15(1):229-41. PubMed ID: 18310290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of clinicopathological features, hormone immunoexpression, and loss of ATRX and DAXX expression in pancreatic neuroendocrine tumors.
    Yadav R; Kakkar A; Sharma A; Malik PS; Sharma MC
    Scand J Gastroenterol; 2016 Aug; 51(8):994-9. PubMed ID: 27162024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study.
    Kim H; An S; Lee K; Ahn S; Park DY; Kim JH; Kang DW; Kim MJ; Chang MS; Jung ES; Kim JM; Choi YJ; Jin SY; Chang HK; Cho MY; Kang YK; Kang M; Ahn S; Kim YW; Hong SM;
    Cancer Res Treat; 2020 Jan; 52(1):263-276. PubMed ID: 31319641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cadherin 17 is frequently expressed by 'sclerosing variant' pancreatic neuroendocrine tumour.
    Johnson A; Wright JP; Zhao Z; Komaya T; Parikh A; Merchant N; Shi C
    Histopathology; 2015 Jan; 66(2):225-33. PubMed ID: 25307987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
    Kaltsas G; Korbonits M; Heintz E; Mukherjee JJ; Jenkins PJ; Chew SL; Reznek R; Monson JP; Besser GM; Foley R; Britton KE; Grossman AB
    J Clin Endocrinol Metab; 2001 Feb; 86(2):895-902. PubMed ID: 11158063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs).
    Cai L; Michelakos T; Deshpande V; Arora KS; Yamada T; Ting DT; Taylor MS; Castillo CF; Warshaw AL; Lillemoe KD; Ferrone S; Ferrone CR
    Clin Cancer Res; 2019 Apr; 25(8):2644-2655. PubMed ID: 30670493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20.
    Konukiewitz B; Schlitter AM; Jesinghaus M; Pfister D; Steiger K; Segler A; Agaimy A; Sipos B; Zamboni G; Weichert W; Esposito I; Pfarr N; Klöppel G
    Mod Pathol; 2017 Apr; 30(4):587-598. PubMed ID: 28059098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cystic pancreatic neuroendocrine tumors: a clinicopathologic study.
    Singhi AD; Chu LC; Tatsas AD; Shi C; Ellison TA; Fishman EK; Kawamoto S; Schulick RD; Wolfgang CL; Hruban RH; Edil BH
    Am J Surg Pathol; 2012 Nov; 36(11):1666-73. PubMed ID: 23073325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonally defined pancreatic and duodenal neuroendocrine tumors differ in their transcription factor signatures: expression of ISL1, PDX1, NGN3, and CDX2.
    Hermann G; Konukiewitz B; Schmitt A; Perren A; Klöppel G
    Virchows Arch; 2011 Aug; 459(2):147-54. PubMed ID: 21739268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression profiles of cadherin 17 and claudin 18.2 in comparison with peptide hormonal expression in pancreatic neuroendocrine tumours: Implications for targeted immunotherapy.
    Maeda K; Uehara T; Hosoda W; Kuraishi Y; Ota H
    Pathol Res Pract; 2024 Oct; 262():155537. PubMed ID: 39178509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic neuroendocrine tumors: Correlation between the contrast-enhanced computed tomography features and the pathological tumor grade.
    Takumi K; Fukukura Y; Higashi M; Ideue J; Umanodan T; Hakamada H; Kanetsuki I; Yoshiura T
    Eur J Radiol; 2015 Aug; 84(8):1436-1443. PubMed ID: 26022520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computed Tomography Features Predictive of Lymph Node Involvement in Patients With a Nonfunctioning Pancreatic Neuroendocrine Tumor.
    Choi SH; Kim HJ; Kim SY; Byun JH; Kim KW; Song KB; Kim SC; Kim MH
    Pancreas; 2017 Sep; 46(8):1056-1063. PubMed ID: 28787330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of nectin-3 expression as a marker of tumor aggressiveness in pancreatic neuroendocrine tumor.
    Hirabayashi K; Tajiri T; Bosch DE; Morimachi M; Miyaoka M; Inomoto C; Nakamura N; Yeh MM
    Pathol Int; 2020 Feb; 70(2):84-91. PubMed ID: 31855317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
    Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
    Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of estrogen-induced genes and estrogen receptor β in pancreatic neuroendocrine tumors: implications for targeted therapy.
    Estrella JS; Ma LT; Milton DR; Yao JC; Wang H; Rashid A; Broaddus RR
    Pancreas; 2014 Oct; 43(7):996-1002. PubMed ID: 25058880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic acinar cell carcinomas and mixed acinar-neuroendocrine carcinomas are more clinically aggressive than grade 1 pancreatic neuroendocrine tumours.
    Kim JY; Brosnan-Cashman JA; Kim J; An S; Lee KB; Kim H; Park DY; Jang KT; Oh YH; Hruban RH; Heaphy CM; Hong SM
    Pathology; 2020 Apr; 52(3):336-347. PubMed ID: 32111396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic gangliocytic paraganglioma harboring lymph node metastasis: a case report and literature review.
    Nonaka K; Matsuda Y; Okaniwa A; Kasajima A; Sasano H; Arai T
    Diagn Pathol; 2017 Aug; 12(1):57. PubMed ID: 28764742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.